Bladder cancer is the sixth most common malignancy in the United States and 70% of cases are non-muscle invasive at the time of diagnosis. Effective treatment is crucial to prevent progression, which occurs in about 30% of patients. The American Urological Association (AUA) guidelines recommend treatment of non-muscle invasive bladder cancer (NMIBC) with intravesical Bacille Calmette-Guerin (BCG) and chemotherapy.Arch Pharmacol Ther, 2022, Volume 4, Issue 1, p13-22 | DOI: 10.33696/Pharmacol.4.030
Relative COVID-19 Vaccine Booster Effectiveness and ClinicalEpidemiological Characteristics Before and After 29 Days of Shot
Background: When the highest vaccine COVID-19 booster effectiveness (VBE) is obtained is not clearly known. Objective: To compare the cases of COVID-19 in booster vaccinated people with a time of <29 days vs. ≥ 29 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective case series study of adult patients with COVID-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave.Arch Pharmacol Ther, 2022, Volume 4, Issue 1, p23-34 | DOI: 10.33696/Pharmacol.4.031
Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant.Arch Pharmacol Ther, 2021, Volume 3, Issue 2, p52-65 | DOI: 10.33696/Pharmacol.3.028
Since the declaration of COVID-19 as a pandemic in March 2020 , there have been more than 100 million reported cases of COVID-19 worldwide and more than 2.1 million deaths .Arch Pharmacol Ther, 2021, Volume 3, Issue 1, p5-9 | DOI: https://doi.org/10.33696/Pharmacol.3.020
Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
Fluoropyrimidines have been extensively used for almost 6 decades to treat a variety of solid cancers, especially colon, gastric, anal, rectal, head & neck and breast. However, 31–34% of patients encountered grade 3–4 adverse events (AEs) with 0.5% mortality oftennecessitating dose reduction or discontinuation.Arch Pharmacol Ther, 2020, Volume 2, Issue 1, p6-8 | DOI: 10.33696/Pharmacol.2.012
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.